Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue tumors. They can occur in patients with neurofibromatosis type-1 (NF-1) or as sporadic tumors. Only 10% of MPNSTs are radiation induced. Divergent differentiation in MPNSTs can occur in 15% of cases and may include cartilage, bone, skeletal muscle, blood vessels, and very rarely well-formed glands, the latter typically described in NF-1–associated MPNSTs. We report an exceedingly rare case of radiation induced glandular MPNST arising in a neurofibroma of the femoral nerve in a patient previously irradiated for endometrial carcinoma.
ToroJRTravisLBWuHJZhuKFletcherCDDevesaSS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006;119:2922-2930.
2.
Le GuellecSDecouvelaereAVFilleronTet al. Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French Sarcoma Group database. Am J Surg Pathol. 2016;40:896-908.
3.
FletcherDMBridgeJAHogendoornPMertensF. World Health Organization Classification of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2013.
UriAKWitzlebenCLRaneyRB. Electron microscopy of glandular schwannoma. Cancer. 1984;53:493-497.
10.
ForakerAG. Glandlike elements in a peripheral neurosarcoma. Cancer. 1948;1:286-293.
11.
MichelSL. Epithelial elements in a malignant neurogenic tumor of the tibial nerve. Am J Surg. 1967;113:404-408.
12.
CrossPAClarkeNW. Malignant nerve sheath tumour with epithelial elements. Histopathology. 1988;12:547-549.
13.
ChristensenWNStrongEWBainsMSWoodruffJM. Neuroendocrine differentiation in the glandular peripheral nerve sheath tumor. Pathologic distinction from the biphasic synovial sarcoma with glands. Am J Surg Pathol. 1988;12:417-426.
14.
KnöselTHeretschSAltendorf-HofmannAet al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer. 2010;46:1170-1176.
15.
TerryJSaitoTSubramanianSet al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007;31:240-246.
16.
JhanwarSCChenQLiFPBrennanMFWoodruffJM. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet. 1994;78:138-144.
17.
LeeWTeckieSWiesnerTet al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227-1232.
18.
De RaedtTBeertEPasmantEet al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247-251.
19.
ZhangMWangYJonesSet al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1170-1172.
20.
SchaeferIMFletcherCDHornickJL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29:4-13.
21.
Prieto-GranadaCNWiesnerTMessinaJLJungbluthAAChiPAntonescuCR. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2016;40:479-489.
